Retirement Systems of Alabama Lowers Stake in Eli Lilly and Company $LLY

Retirement Systems of Alabama reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the second quarter, Holdings Channel reports. The firm owned 168,793 shares of the company’s stock after selling 526 shares during the period. Retirement Systems of Alabama’s holdings in Eli Lilly and Company were worth $131,579,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Covestor Ltd raised its holdings in shares of Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after acquiring an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $242,000. Finally, Golden State Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 9.1% in the first quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company’s stock valued at $842,000 after acquiring an additional 85 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a report on Sunday, August 17th. Berenberg Bank restated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $810.78 on Thursday. The company has a market capitalization of $767.37 billion, a PE ratio of 52.99, a P/E/G ratio of 1.22 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a 50-day simple moving average of $775.02 and a two-hundred day simple moving average of $770.34. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.